The MEDICE Health Family
The MEDICE health family is proud to bring innovative, integrated and diverse healthcare solutions to those who need it. Explore our family roots, how we got to where we are today, and our vision and mission - inspiring every member of our health family in the UK, driving us forward.
Our aspiration lives at the heart of our vision
Our vision statement outlines where we want to go in the coming years and defines a clear goal, uniting all of us across the UK MEDICE health family
Based on our long-standing tradition as a family-run company, we will shape the future of medicine over the coming decade. We will become a leading global developer and provider of innovative, integrated and highly diverse healthcare solutions.
We are the Health Family for our patients, doctors, nurses, pharmacists, employees and partners.
Improving the health and lives of people in as many areas as possible is what motivates us on a daily basis.
We develop integrated solutions to help people in every phase of their illness by resolutely focusing on the needs of patients, doctors, nurses and pharmacists.
In this process, we always act responsibly and sustainably as a Health Family for the benefit of people and the environment.
Our mission will help us achieve our goal
Our mission statement explains our ‘why’ and our motivation that drives our daily work, making our vision come alive
A look back at where it all began
-
1949
In post-war Germany Gustav Putter created MEDICE Arzneimittel GmbH to supply OTC medicines to his local community.
Gustav's son, Sigurd, transformed MEDICE into a modern pharmaceutical company in the 80s.
-
90s
MEDICE developed the medicine, Medikinet® (methylphenidate hydrochloride).
-
2002
Sigurd’s daughter, Dr Katja Pütter-Ammer joined MEDICE, shortly followed by her husband, Dr Richard Ammer.
-
2004
Medikinet® (methylphenidate hydrochloride) launched in Germany.
-
2005
Medikinet® XL ▼ (methylphenidate hydrochloride) launched in Germany.
-
2007
Medikinet® XL ▼ (methylphenidate hydrochloride) is made available in the UK through a partner organisation.
-
2015
Amfexa® (dexamfetamine sulfate) medication was launched.
-
2023
MEDICE UK took back the management of its treatment portfolio and began the journey to launch their treatments in the UK.
-
2024
MEDICE UK repatriated Nephrotrans® (sodium hydrogen carbonate) from a partner organisation. Velariq® (oxybutynin hydrochloride) was launched by MEDICE UK.
Our MEDICE Health Family
Our aim is to develop suitable preventative solutions and treatments for every stage of disease. From initial diagnosis through to chronic symptom management.
Our integrated structure brings together expertise within the MEDICE Health Family so we can bring our vision to life.
Our main areas of focus:
- Pharmaceuticals
- Digital health
HCP Payment Transparency
MEDICE values its collaborative efforts; by working with the NHS, its dedicated staff, and patient groups, we strive to enhance patient outcomes and ensure optimal care. MEDICE actively participates in the Association of British Pharmaceutical Industry’s (ABPI) Disclosure UK initiative. This commitment reflects our dedication to transparency regarding relationships with healthcare professionals, including doctors, nurses, and pharmacists. We encourage all parties to disclose payment details, fostering openness and accountability across our stakeholder network.
To access MEDICE latest disclosures, please click here
Or view our Transfer of Value Methodological Note
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare Professionals are asked to report any suspected adverse reactions.
Date of Preparation: August 2024 UK-COR-2024-1640-v1
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should be reported to MEDICE UK, Medical Information Tel: 0204 582 2845, medicalinformation@medice.co.uk